INSTRUMENT FOR BRAIN CELL IMPLATATION

描述：(申请人摘要)立体定向手术允许在 大脑深处的结构，同时最大限度地减少对以上和 围绕着目标建筑。传统上，神经外科干预有 包括切除病变组织。然而，一个新兴的应用程序 神经外科技术的核心是细胞植入(神经移植)， 营养因子、基因、化学疗法、神经活性化合物或其他 治疗药物新鲜组织或神经干细胞的神经移植 作为一种重建细胞群体的方法，补充 局部产生的大脑化学物质的水平，并重建神经 电路。 尽管取得了一些成功，但脑细胞注射后的功能恢复 到目前为止是温和的，具有很高的变异性。边际功能恢复是 与移植细胞存活率差直接相关。改进了 细胞存活将有助于这一潜在强大的 治疗方法。 大量研究表明，细胞存活率在以下情况下提高 注射器更小，注射量更小。单元格 通过拉动的玻璃微吸管传输的数据增加了250% 通过0.5毫米注射的细胞存活。不锈钢套管。 人体外科常用的注射器为0.5-1毫米。在直径上。这 建议开发一种脑内微量注射器，用于 通过多次注射，将少量细胞植入大脑深处 网站，具有最小的侵入性损害。在第一阶段，我们开发了一个 工具和概念的示范证明。此设备将扩展到 人类的长度，并在疾病的动物模型中再次进行测试。我们将表演所有 获得FDA批准作为研究设备所需的测试 人类。 建议的商业应用： 不可用

DESCRIPTION: (Applicant's abstract) Stereotactic surgery allows procedures on structures deep within the brain, while minimizing damage to tissue above and surrounding the target structure. Traditionally, neurosurgical intervention has involved the removal of pathological tissues. However, an emerging application of neurosurgical technique is the insertion of cells (neurotransplantation), trophic factors, genes, chemo-therapeutics, neuroactive compounds, or other therapeutic agents Neurotransplantation of fresh tissue or neural stem cells holds promise as a method of reconstituting cell populations, supplementing levels of locally produced brain chemicals, and re-establishing neural circuitry. Despite some successes, functional recovery following brain cell injections has to date been modest, with high variability. Marginal functional recovery is directly associated with poor survival of the implanted cells. Improvements in cell survival would contribute to the utility of this potentially powerful therapeutic approach. Numerous studies have demonstrated that cell survival is increased when the injection instrument is smaller and the injection volume is reduced. Cells delivered through a pulled glass micropipette have 250 percent increased survival over cells injected through a 0.5 mm. stainless steel cannula. Commonly used injectors for human surgery are 0.5-1 mm. in diameter. This proposal is to develop an intracerebral microinjection instrument for implanting small volumes of cells deep within the brain, at multiple injection sites, with a minimum of invasive damage. In Phase I, we developed an instrument and demonstrated proof of concept. This device will be scaled to human length, and tested again in animal models of disease. We will perform all testing necessary to obtain FDA approval as an investigational device in humans. PROPOSED COMMERCIAL APPLICATION: Not avaliable